Nothing Special   »   [go: up one dir, main page]

LT3302550T - Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas - Google Patents

Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas

Info

Publication number
LT3302550T
LT3302550T LT16725504T LT16725504T LT3302550T LT 3302550 T LT3302550 T LT 3302550T LT 16725504 T LT16725504 T LT 16725504T LT 16725504 T LT16725504 T LT 16725504T LT 3302550 T LT3302550 T LT 3302550T
Authority
LT
Lithuania
Prior art keywords
antibody
tyrosine kinase
kinase inhibitor
inhibitor combination
bruton tyrosine
Prior art date
Application number
LT16725504T
Other languages
English (en)
Inventor
Jan Endell
Rainer Boxhammer
Mark Winderlich
Original Assignee
Morphosys Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Morphosys Ag filed Critical Morphosys Ag
Publication of LT3302550T publication Critical patent/LT3302550T/lt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/395Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39558Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/70Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/73Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
    • C07K2317/732Antibody-dependent cellular cytotoxicity [ADCC]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Organic Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Genetics & Genomics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Mycology (AREA)
  • Microbiology (AREA)
  • Oncology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Endocrinology (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
LT16725504T 2015-05-26 2016-05-25 Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas LT3302550T (lt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
EP15169124 2015-05-26
EP15196860 2015-11-27
PCT/EP2016/061744 WO2016189014A1 (en) 2015-05-26 2016-05-25 Combination of an anti-cd19 antibody and a bruton's tyrosine kinase inhibitor and uses thereof

Publications (1)

Publication Number Publication Date
LT3302550T true LT3302550T (lt) 2019-11-11

Family

ID=56084030

Family Applications (1)

Application Number Title Priority Date Filing Date
LT16725504T LT3302550T (lt) 2015-05-26 2016-05-25 Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas

Country Status (24)

Country Link
US (3) US10617691B2 (lt)
EP (2) EP3302550B1 (lt)
JP (4) JP6916741B2 (lt)
KR (1) KR102809079B1 (lt)
CN (2) CN114601931B (lt)
AU (3) AU2016266708B2 (lt)
CA (1) CA2986175A1 (lt)
CY (1) CY1122298T1 (lt)
DK (1) DK3302550T3 (lt)
ES (1) ES2754431T3 (lt)
HK (1) HK1251152B (lt)
HR (1) HRP20192100T1 (lt)
HU (1) HUE046328T2 (lt)
IL (2) IL255377B (lt)
LT (1) LT3302550T (lt)
NZ (1) NZ736820A (lt)
PL (1) PL3302550T3 (lt)
PT (1) PT3302550T (lt)
RS (1) RS59605B1 (lt)
RU (1) RU2756010C2 (lt)
SI (1) SI3302550T1 (lt)
SM (1) SMT201900647T1 (lt)
WO (1) WO2016189014A1 (lt)
ZA (1) ZA201707867B (lt)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN107936121B (zh) 2011-05-16 2022-01-14 埃泰美德(香港)有限公司 多特异性fab融合蛋白及其使用方法
PL3337506T3 (pl) 2015-08-21 2022-01-03 Morphosys Ag Kombinacje i ich zastosowania
CA3017776A1 (en) 2016-03-15 2017-09-21 Generon (Shanghai) Corporation Ltd. Multispecific fab fusion proteins and use thereof
CN116120454A (zh) * 2017-01-05 2023-05-16 上海煦顼技术有限公司 人源化抗cd19抗体及其与嵌合抗原受体的用途
CN110945028B (zh) 2017-07-10 2023-09-08 国际药物发展生物技术公司 用非岩藻糖基化促凋亡抗cd19抗体与抗cd20抗体或化疗剂联合治疗b细胞恶性肿瘤
JP7548587B2 (ja) * 2018-09-07 2024-09-10 アイタブメッド (エイチケイ) リミテッド 二重特異性抗原結合タンパク質及びその使用
KR20200030337A (ko) * 2018-09-12 2020-03-20 주식회사 녹십자랩셀 종양 치료를 위한 항-cd 19 항체 및 자연살해세포를 포함하는 약학적 조합물
IL292213A (en) * 2019-10-31 2022-06-01 Morphosys Ag Anti-tumor combination therapy comprising anti-cd19 antibody and gamma delta t-cells
CN114786723A (zh) * 2019-10-31 2022-07-22 莫佛塞斯公司 序贯抗cd19疗法
JP2023551519A (ja) * 2020-11-30 2023-12-08 インサイト・コーポレイション 抗cd19抗体とパルサクリシブの組み合わせ療法
WO2022115120A1 (en) * 2020-11-30 2022-06-02 Incyte Corporation Combination therapy with an anti-cd19 antibody and parsaclisib
WO2024037594A1 (en) * 2022-08-19 2024-02-22 Beijing Innocare Pharma Tech Co., Ltd. Combination treatment with orelabrutinib and tafasitamab
KR102655236B1 (ko) 2024-01-02 2024-04-08 한화시스템(주) 빔 조향범위 확장 구조를 가지는 저궤도 통신위성 배열안테나

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0138854B1 (en) 1983-03-08 1992-11-04 Chiron Mimotopes Pty. Ltd. Antigenically active amino acid sequences
US5686072A (en) 1992-06-17 1997-11-11 Board Of Regents, The University Of Texas Epitope-specific monoclonal antibodies and immunotoxins and uses thereof
MXPA03002262A (es) 2000-09-18 2003-10-15 Idec Pharma Corp Terapia de combinacion para tratamiento de enfermedades autoinmunes usando una combinacion de anticuerpos inmunorreguladores/supresores de celulas b.
WO2003048731A2 (en) 2001-12-03 2003-06-12 Abgenix, Inc. Antibody categorization based on binding characteristics
US7902338B2 (en) 2003-07-31 2011-03-08 Immunomedics, Inc. Anti-CD19 antibodies
WO2005012493A2 (en) 2003-07-31 2005-02-10 Immunomedics, Inc. Anti-cd19 antibodies
WO2007002223A2 (en) 2005-06-20 2007-01-04 Medarex, Inc. Cd19 antibodies and their uses
DK2270050T3 (da) 2005-12-30 2013-08-12 Merck Patent Gmbh Anti-CD19-antistoffer med nedsat immunogenicitet
PT2383297E (pt) 2006-08-14 2013-04-15 Xencor Inc Anticorpos otimizados que visam cd
WO2008031056A2 (en) 2006-09-08 2008-03-13 Medimmune, Llc Humanized anti-cd19 antibodies and their use in treatment of oncology, transplantation and autoimmune disease
ES2584331T3 (es) 2006-09-22 2016-09-27 Pharmacyclics Llc Inhibidores de tirosina cinasa de Bruton
EP2708557A1 (en) 2007-05-30 2014-03-19 Xencor, Inc. Method and compositions for inhibiting CD32B expressing cells
PT2211904T (pt) 2007-10-19 2016-11-02 Seattle Genetics Inc Agentes de ligação a cd19 e seus usos
SG173654A1 (en) 2009-02-23 2011-09-29 Glenmark Pharmaceuticals Sa Humanized antibodies that bind to cd19 and their uses
US20120128586A1 (en) 2009-06-24 2012-05-24 The Feinstein Institute For Medical Research Method for treating chronic lymphocytic leukemia
WO2011147834A1 (en) 2010-05-26 2011-12-01 Roche Glycart Ag Antibodies against cd19 and uses thereof
CA3007787C (en) * 2010-06-03 2020-03-10 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk)
EP2409993A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC function with improved glycosylation profile
EP2409712A1 (en) 2010-07-19 2012-01-25 International-Drug-Development-Biotech Anti-CD19 antibody having ADCC and CDC functions and improved glycosylation profile
EP2524929A1 (en) 2011-05-17 2012-11-21 Sanofi Use of anti-CD19 maytansinoid immunoconjugate antibody for the treatment of CD19+ B-cell malignancies syptoms
KR20180084153A (ko) 2011-06-10 2018-07-24 메르크 파텐트 게엠베하 Btk 억제 활성을 갖는 피리미딘 및 피리딘 화합물의 조성물 및 제조방법
EP2548877A1 (en) 2011-07-19 2013-01-23 MSD Oss B.V. 4-(5-Membered fused pyridinyl)benzamides as BTK-inhibitors
KR102117202B1 (ko) 2011-08-16 2020-06-01 모르포시스 아게 항cd19 항체 및 퓨린 유사체를 이용한 병용 요법
DK2744515T3 (da) 2011-08-16 2022-03-28 Morphosys Ag Kombinationsterapi med et anti-cd19-antistof og en nitrogensennep
AR092790A1 (es) * 2012-02-01 2015-05-06 Euro Celtique Sa Derivados bencimidazolicos del acido hidroxamico
EP2890691B1 (en) * 2012-08-31 2018-04-25 Principia Biopharma Inc. Benzimidazole derivatives as itk inhibitors
WO2014113932A1 (en) 2013-01-23 2014-07-31 Merck Sharp & Dohme Corp. Btk inhibitors

Also Published As

Publication number Publication date
US20180153892A1 (en) 2018-06-07
IL255377A (en) 2018-02-28
JP2023058502A (ja) 2023-04-25
EP3302550A1 (en) 2018-04-11
EP3603672A1 (en) 2020-02-05
CN114601931B (zh) 2023-09-01
US20240009196A1 (en) 2024-01-11
AU2024201029A1 (en) 2024-03-14
US10617691B2 (en) 2020-04-14
US20200206228A1 (en) 2020-07-02
AU2016266708B2 (en) 2022-02-03
CN107660151B (zh) 2022-03-11
JP2021152029A (ja) 2021-09-30
HRP20192100T1 (hr) 2020-02-21
ZA201707867B (en) 2021-03-31
ES2754431T3 (es) 2020-04-17
AU2016266708A1 (en) 2017-11-16
RU2017143166A3 (lt) 2019-11-28
IL287433A (en) 2021-12-01
CY1122298T1 (el) 2021-01-27
DK3302550T3 (da) 2019-11-04
SMT201900647T1 (it) 2020-01-14
CN114601931A (zh) 2022-06-10
AU2022202796B2 (en) 2023-11-23
PL3302550T3 (pl) 2020-02-28
JP6916741B2 (ja) 2021-08-11
NZ736820A (en) 2025-02-28
JP2018516905A (ja) 2018-06-28
IL255377B (en) 2021-12-01
CA2986175A1 (en) 2016-12-01
KR20180004286A (ko) 2018-01-10
RU2756010C2 (ru) 2021-09-24
RU2017143166A (ru) 2019-06-27
HUE046328T2 (hu) 2020-03-30
AU2022202796A1 (en) 2022-05-19
RS59605B1 (sr) 2020-01-31
WO2016189014A1 (en) 2016-12-01
HK1251152B (en) 2020-04-24
SI3302550T1 (sl) 2020-01-31
PT3302550T (pt) 2019-11-26
EP3302550B1 (en) 2019-08-28
KR102809079B1 (ko) 2025-05-21
JP2025016532A (ja) 2025-02-04
CN107660151A (zh) 2018-02-02

Similar Documents

Publication Publication Date Title
LT3302550T (lt) Anti-cd19 antikūno ir brutono tirozino kinazės inhibitoriaus derinys ir jo naudojimas
IL262095A (en) Anti-pacap antibodies and uses thereof
MA43162A (fr) Inhibiteurs de type imidazopyrazine de tyrosine kinase de bruton
LT3353212T (lt) Optimizuoti anti-cd3 bispecifiniai antikūnai ir jų naudojimas
BR112017002232A2 (pt) combinações de inibidor de tirosina quinase de bruton e usos das mesmas
LT3368534T (lt) Valbenazino ditozilatas ir jo polimorfai
LT3274370T (lt) Antikūnai prieš ceacam6 ir jų panaudojimas
MA42623A (fr) Inhibiteurs de la tyrosine kinase de bruton
KR20180084817A (ko) 항-siglec-9 항체 및 이의 이용 방법
LT3280441T (lt) Anti-sortilino antikūnai ir jų naudojimo būdai
IL269122A (en) Anti-c5 antibodies and uses thereof
LT3258951T (lt) Anti-pvrig antikūnai ir jų panaudojimo būdai
DK3303334T3 (da) Tyrosinkinasehæmmere
LT3560924T (lt) Imidazolonilchinolinai ir jų panaudojimas kaip atm kinazės inhibitorių
LT3205650T (lt) Egfr inhibitorius ir jo gavimas bei taikymas
LT3394065T (lt) Tetrahidropiranilamino-pirolopirimidinonas ir jo panaudojimo būdai
MA42242A (fr) Inhibiteurs de la tyrosine kinase
LT3256218T (lt) Kdm1a inhibitorius ir jo panaudojimas terapijoje
LT3126388T (lt) Antikūnai prieš egfrviii ir jų panaudojimo būdai
KR102068915B9 (ko) 조직 인자 경로 억제제 항체 및 그의 용도
BR112017010262A2 (pt) combinações de inibidor de tlr e inibidor de turosina-quinas de bruton
EP3405192A4 (en) BRUTON TYROSINE KINASE HEMMER
DK3327036T3 (da) Tumor-specifikt anti-EGFR-antistof samt anvendelse deraf
PT3359563T (pt) Recetores de antigénios e suas utilizações
EP3601264A4 (en) Bruton's tyrosine kinase inhibitors